Skip to content
FDA ApprovedGLP-1✓ Free to read

Semaglutide

Also called Ozempic / Wegovy

The shot that put weight-loss drugs on magazine covers, and the only one also proven to protect your heart.

Updated 19 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A weekly shot that copies the gut hormone GLP-1 (brands Ozempic, Wegovy)
Is it FDA-approved?
Yes, for weight loss, type 2 diabetes, and heart protection
How strong is the proof?
Very strong. Huge human trials, including a heart study
How you take it
A small shot under the skin, once a week, building up slowly
Typical result
About 14.9% of body weight lost in the main trial
Biggest catch
Upset stomach early. The weight comes back if you stop

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Semaglutide is a medicine you inject once a week. You may know the brand names: Ozempic and Wegovy.

Your gut makes a hormone called that tells your brain you are full. Semaglutide copies that hormone. It slows how fast your stomach empties and turns down your appetite. So you feel hungry less often, you eat less, and you lose weight.

It is . That means the U.S. government checked it in large studies and agreed it is safe and works.

This is the drug that started the whole "weight-loss shot" conversation.

What people use it for.

Most people take semaglutide to lose weight.

Doctors also use it for type 2 diabetes, because it lowers blood sugar.

There is one more big reason. In people who already have heart disease, it cut the risk of major heart problems. So a doctor may use it to protect the heart, not just for the scale.

Does it actually work?

Yes. This is one of the best-studied weight-loss drugs we have.

In the main trial (called STEP-1, 1,961 people), people lost about 14.9% of their body weight in 68 weeks. For someone who weighs 250 pounds, that is around 37 pounds.

In a huge heart trial (called SELECT, 17,604 people), it cut major heart events by about 20% in people who already had heart disease. That is a real, separate reason to take it.

The honest catch: the weight comes back if you stop. In one study, people who quit regained about two-thirds of their lost weight within a year. Most people who do well stay on it long-term or come off slowly with a real plan.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

It melts fat, people lose around 15% of their weight.

true

In the main trial of nearly 2,000 people, the average loss was about 14.9% over 68 weeks. For a 250-pound person that is roughly 37 pounds. This is one of the best-studied weight drugs there is.

The weight just comes right back the second you stop.

mostly true

In one study people regained about two-thirds of the lost weight within a year of quitting. It works while you are on it, so the people who keep it off stay on long-term or taper off with a real plan.

It also protects your heart.

true

In a trial of more than 17,000 people who already had heart disease, it cut major heart events by about 20%. That is a real, separate reason a doctor might prescribe it.

It's only for diabetics, using it to lose weight is misuse.

myth

It is for weight loss under the name Wegovy, not only for diabetes. Same drug, two approved jobs.

It causes muscle loss and gives you Ozempic face.

half true

Any large weight loss takes some muscle and some facial fat with it, no matter how you do it. That is the weight dropping, not a special effect of this shot. Strength work and enough protein blunt it.

How you take it.

You take it as a small shot under the skin (), once a week. People do it in the belly, thigh, or upper arm.

You start at a low dose and go up slowly. That slow climb is called . Starting low gives your stomach time to adjust, so you feel less sick.

There is a ladder of doses that rises about every 4 weeks up to the full amount. If a dose is working and you feel fine, there is no rush to climb higher.

What to watch out for.

The common stuff

Most side effects are stomach problems: nausea, throwing up, diarrhea, or being backed up. They are usually worst right after you go up a dose, and they ease over time. Smaller meals and going up slowly help a lot.

The serious stuff

  • It carries the FDA's strongest warning (a "black box") for a rare thyroid cancer. Do not use it if you or a close family member has had this cancer, or a condition called MEN-2.
  • If you have had pancreatitis (a swollen pancreas), be careful and stop if your doctor suspects it again.
  • It slows your stomach, which can change how other pills work. That includes thyroid medicine (levothyroxine), the blood thinner warfarin, diabetes pills, and birth control pills. Your doctor may need to check your levels more often. Use a backup birth control method to be safe.
  • If you also take insulin, watch for low blood sugar. Do not both at full dose without a doctor.

If anything feels wrong, talk to a real doctor. We are not your doctor.

Where people get it.

Here are the lanes from safest to riskiest.

  • Brand (Ozempic / Wegovy / Rybelsus). The real pharmacy product with a prescription. Safest. The list price is high, but Novo's own self-pay service (NovoCare) cuts it to about $199 to $349 a month.
  • . Made by special pharmacies, about $169 to $499 a month. But semaglutide came off the FDA shortage list in May 2025, so most of these have shut down or moved on. The legal cover is mostly gone.
  • Research-only (). Cheap, about $30 to $100 a month, sold "for research only." You mix it yourself. Highest risk for what is really inside.
  • . Overseas raw powder, the cheapest per dose. Illegal to import for human use, and the most variable.

One scam to know: stay away from vials labeled "semaglutide + B12" or "semaglutide blend." That mix is a common way to water down the real drug, so you get less than you paid for. The cleanest product is semaglutide on its own. If you buy research-grade, ask for a , a lab report showing what is really in the vial.

Our honest take.

There is a bonus hiding in this one
Semaglutide is the famous one (Ozempic and Wegovy), and it is the only weight-loss shot also proven to cut heart attacks and strokes. A trial of more than 17,000 people found about 20% fewer heart events. On the scale, people lost around 15% of their body weight: think 200 pounds dropping to about 170. That is a little less than tirzepatide, but in the same league.

So the choice is simple. If your heart is part of the picture, this is the pick. If you only want the biggest number, tirzepatide edges it.

The honest catch is the same for the whole family: it works while you are on it, so plan for the long haul and get it from a clean source. The brand is cheap enough now (NovoCare self-pay) that there is little reason to gamble on a mystery vial from a tele-clinic.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Smits MM, et al. Safety of Semaglutide. Frontiers in endocrinology. 2021;12:645563. PMID: 34305810.
  2. 02Chao AM, et al. Semaglutide for the treatment of obesity. Trends in cardiovascular medicine. 2023;33(3):159-166. PMID: 34942372.
  3. 03Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021;397(10278):971-984. PMID: 33667417.
  4. 04Tan HC, et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies. 2022;37(2):65-72. PMID: 36578889.
  5. 05Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. 2020;5(6). PMID: 32213703.
  6. 06Singh G, et al. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2022;70(1):5-13. PMID: 34706925.
  7. 07Yang XD, et al. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug design, development and therapy. 2024;18:2555-2570. PMID: 38952487.
  8. 08Bikou A, et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy. 2024;25(5):611-619. PMID: 38629387.
  9. 09Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA ophthalmology. 2024;142(8):732-739. PMID: 38958939.
  10. 10Karagiannis T, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206-1222. PMID: 38613667.
  11. 11Dhillon S. Semaglutide: First Global Approval. Drugs. 2018;78(2):275-284. PMID: 29363040.
  12. 12Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes & endocrinology. 2017;5(4):251-260. PMID: 28110911.
  13. 13Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology. 2018;6(4):275-286. PMID: 29397376.
  14. 14Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Frontiers in endocrinology. 2021;12:645617. PMID: 34248838.
  15. 15Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism. 2017;19(9):1242-1251. PMID: 28266779.
  16. 16Suran M. As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss. JAMA. 2023;329(19):1627-1629. PMID: 37099334.
  17. 17Li X, et al. Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction. Redox biology. 2024;72:103129. PMID: 38574433.
  18. 18Bensignor MO, et al. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice. Current opinion in pediatrics. 2024;36(4):449-455. PMID: 38774967.
  19. 19Aroda VR, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & metabolism. 2019;45(5):409-418. PMID: 30615985.
  20. 20Irfan H. Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial. Current problems in cardiology. 2024;49(1 Pt A):102060. PMID: 37640171.
  21. 21Kadowaki T, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2022;10(3):193-206. PMID: 35131037.
  22. 22Andreadis P, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, obesity & metabolism. 2018;20(9):2255-2263. PMID: 29756388.
  23. 23Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism. 2021;23(3):754-762. PMID: 33269530.
  24. 24Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024;20(12):8661-8672. PMID: 39445596.
  25. 25Chuong V, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI insight. 2023;8(12). PMID: 37192005.
  26. 26MacIsaac RJ. Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. Future cardiology. 2025;21(9):663-683. PMID: 40458885.
  27. 27Masson W, et al. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinologia, diabetes y nutricion. 2024;71(3):124-132. PMID: 38555109.
  28. 28Feier CVI, et al. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International journal of molecular sciences. 2024;25(8). PMID: 38673931.
  29. 29Krüger N, et al. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2025;334(14):1255-1266. PMID: 40886075.
  30. 30Amini A, et al. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association. Acta ophthalmologica. 2025;103(6):615-621. PMID: 40055951.
  31. 31Rivera FB, et al. Evaluating the safety profile of semaglutide: an updated meta-analysis. Current medical research and opinion. 2024;40(9):1495-1514. PMID: 39046272.
  32. 32Niu S, et al. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Frontiers in endocrinology. 2022;13:1046130. PMID: 36568109.
  33. 33Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The lancet. Diabetes & endocrinology. 2021;9(9):563-574. PMID: 34293304.
  34. 34Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642. PMID: 37295046.
  35. 35Zhang HD, et al. Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. Diabetes & metabolic syndrome. 2024;18(6):103067. PMID: 38955095.
  36. 36Mao T, et al. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochemical and biophysical research communications. 2024;710:149882. PMID: 38583231.
  37. 37Zhu Q, et al. Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway. Biochemical and biophysical research communications. 2023;647:1-8. PMID: 36706596.
  38. 38Skov K, et al. Semaglutide and pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2023;163(2):699-700. PMID: 37688299.
  39. 39Overgaard RV, et al. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics. 2021;60(10):1335-1348. PMID: 33969456.
  40. 40Haseeb M, et al. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss. JAMA network open. 2024;7(4):e246221. PMID: 38607627.
  41. 41Davies M, et al. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(15):1460-1470. PMID: 29049653.
  42. 42Mawardi HH, et al. Semaglutide-associated hyposalivation: A report of case series. Medicine. 2023;102(52):e36730. PMID: 38206684.
  43. 43Wen J, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinology, diabetes & metabolism. 2025;8(3):e70045. PMID: 40184508.
  44. 44Lee TS, et al. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2023;1221:123688. PMID: 36989942.
  45. 45Wharton S, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.). 2023;31(3):703-715. PMID: 36655300.
  46. 46Amaro A, et al. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate medicine. 2022;134(sup1):5-17. PMID: 36691309.
  47. 47Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism. 2020;46(2):100-109. PMID: 31539622.
  48. 48Wang F, et al. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Clinical drug investigation. 2022;42(1):17-28. PMID: 34894326.
  49. 49Ahrén B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet. Diabetes & endocrinology. 2017;5(5):341-354. PMID: 28385659.
  50. 50Hall S, et al. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clinical pharmacokinetics. 2018;57(12):1529-1538. PMID: 29915923.
  51. 51Ezhilarasan D. Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?. Journal of gastroenterology and hepatology. 2025;40(9):2163-2175. PMID: 40538007.
  52. 52Kommu S, et al. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2024;25(9):e13792. PMID: 38923272.
  53. 53Barbagelata L, et al. Semaglutide and heart failure: Updated meta-analysis. Current problems in cardiology. 2024;49(9):102721. PMID: 38908729.
  54. 54Jensen L, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017;104:31-41. PMID: 28323117.
  55. 55Christou GA, et al. Semaglutide as a promising antiobesity drug. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2019;20(6):805-815. PMID: 30768766.
  56. 56de Paiva IHR, et al. Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2024;19(1):36. PMID: 39042202.
  57. 57Lexchin J, et al. Semaglutide: a new drug for the treatment of obesity. Drug and therapeutics bulletin. 2023;61(12):182-188. PMID: 37879878.
  58. 58Basile L, et al. Semaglutide and obesity: beyond the nutritional and lifestyle intervention?. Minerva endocrinology. 2024;49(2):182-195. PMID: 39028209.
  59. 59Gibbons C, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, obesity & metabolism. 2021;23(2):581-588. PMID: 33184979.
  60. 60Duan X, et al. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet. European journal of pharmacology. 2024;969:176440. PMID: 38402930.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.